MX2013000760A - Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina. - Google Patents

Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina.

Info

Publication number
MX2013000760A
MX2013000760A MX2013000760A MX2013000760A MX2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A MX 2013000760 A MX2013000760 A MX 2013000760A
Authority
MX
Mexico
Prior art keywords
dopamine
dopa
agents
individual
disorders
Prior art date
Application number
MX2013000760A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Alexander Howson
Original Assignee
Phytopharm Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Plc filed Critical Phytopharm Plc
Publication of MX2013000760A publication Critical patent/MX2013000760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2013000760A 2010-07-20 2011-07-20 Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina. MX2013000760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36601510P 2010-07-20 2010-07-20
PCT/GB2011/051376 WO2012010896A1 (en) 2010-07-20 2011-07-20 Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders

Publications (1)

Publication Number Publication Date
MX2013000760A true MX2013000760A (es) 2013-10-28

Family

ID=44583771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000760A MX2013000760A (es) 2010-07-20 2011-07-20 Tratamiento de trastornos inducidos por l-dopa, agonista de la dopamina y/o potenciador de dopamina.

Country Status (13)

Country Link
US (1) US20130210786A1 (enExample)
EP (1) EP2595621A1 (enExample)
JP (1) JP2013543482A (enExample)
KR (1) KR20130043197A (enExample)
CN (1) CN103189056A (enExample)
AU (1) AU2011281336B2 (enExample)
BR (1) BR112013001422A2 (enExample)
CA (1) CA2805693A1 (enExample)
EA (1) EA201390070A1 (enExample)
MX (1) MX2013000760A (enExample)
SG (1) SG187090A1 (enExample)
WO (1) WO2012010896A1 (enExample)
ZA (1) ZA201301231B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
WO2013183055A1 (en) 2012-06-05 2013-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
JP2017008044A (ja) * 2015-06-22 2017-01-12 学校法人 久留米大学 ドーパミンシグナル伝達の抑制剤
CN105106230A (zh) * 2015-08-16 2015-12-02 南京华宽信息咨询中心 一种单胺氧化酶mao抑制剂及其应用
BR112022001595A2 (pt) * 2019-07-29 2022-03-22 Peptron Inc Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa
US20210100737A1 (en) 2019-10-03 2021-04-08 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
EP4088721B1 (en) * 2020-01-08 2025-09-17 Neuroventi Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CN115282156A (zh) * 2022-09-05 2022-11-04 广东海洋大学 知母皂苷元在制备防治帕金森病的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA985172A (en) 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
EP0102416A1 (en) 1982-08-23 1984-03-14 Nutrisearch Company Blends of egg albumen and whey protein of improved gel strength
US4680289A (en) 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
CA2096853A1 (en) * 1990-11-24 1992-05-25 Anthony Michael Johnson Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
JP4740426B2 (ja) 1997-03-17 2011-08-03 ビーティージー・インターナショナル・リミテッド 治療用組成物
CN1131237C (zh) 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
DK1066042T3 (da) 1998-03-26 2006-12-18 Phytopharm Plc Steroidale saponiner til behandling af Alzheimers sygdom
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9905275D0 (en) 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
EP1123094B1 (en) 1998-09-15 2007-04-11 Btg International Limited Therapeutic compositions (ii)
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
GB9923078D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
GB0107822D0 (en) 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
MXPA04009321A (es) * 2002-03-27 2005-01-25 Phytopharm Plc Metodos y usos terapeuticos de sapogeninas y sus derivados.
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
WO2003082893A2 (en) 2002-03-27 2003-10-09 Phytopharm Plc Theraputic methods and uses of sapogenins and their derivatives
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0424528D0 (en) 2004-11-05 2004-12-08 Phytopharm Plc Chemical compounds
US20070041924A1 (en) * 2005-08-19 2007-02-22 Bioderm Research Sebum Control Compositions Based on Saponins and Sapogenins
EA201190115A1 (ru) * 2009-01-24 2012-02-28 ФИТОФАРМ ПиЭлСи Лечение расстройств, опосредованных нейротрофическим фактором

Also Published As

Publication number Publication date
CA2805693A1 (en) 2012-01-26
BR112013001422A2 (pt) 2019-09-24
EP2595621A1 (en) 2013-05-29
SG187090A1 (en) 2013-02-28
US20130210786A1 (en) 2013-08-15
ZA201301231B (en) 2014-04-30
AU2011281336B2 (en) 2015-03-05
JP2013543482A (ja) 2013-12-05
WO2012010896A1 (en) 2012-01-26
CN103189056A (zh) 2013-07-03
EA201390070A1 (ru) 2013-09-30
AU2011281336A1 (en) 2013-01-31
KR20130043197A (ko) 2013-04-29

Similar Documents

Publication Publication Date Title
AU2011281336B2 (en) Treatment of L-DOPA, dopamine agonist and/or dopamine enhancer induced disorders
Merello et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
MX2011007842A (es) Tratamiento de trastornos mediados por factores neurotroficos.
CN106692122A (zh) 以5‑氨基乙酰丙酸或其衍生物、或它们的盐作为有效成分的成人病的预防、改善剂
AU2002336765B2 (en) Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
JP7758320B2 (ja) ５－ヒドロキシトリプトファンのバイオアベイラビリティを高める組成物および方法
CN101657194A (zh) 包含葫芦巴碱和4-羟基异亮氨酸的药物组合物及其方法
WO2012113079A1 (en) Cystamine analogues for the treatment of parkinson's disease
JP2023506480A (ja) アルツハイマー病の治療のための化合物
WO2006043532A1 (ja) パーキンソン病治療剤
EP0207011A2 (en) Use of some alkanoyl L-carnitines for the manufacture of a medicament for therapeutical treatment of idiopathic and induced Parkinsonism
US20130017274A1 (en) Low dose lithium in the treatment or prophylaxis of parkinson's disease
CA3186900A1 (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
JP2022057307A (ja) アンモニア代謝促進剤
EP1909782B1 (en) Compositions comprising arginine and r-alpha-lipoic acid and their use for improvement of sexual function
WO2020110128A1 (en) Combination of pridopidine and an additional therapeutic agent for treating drug induced dyskinesia
CN109562089A (zh) 苯甲酸锂用于治疗中枢神经系统疾病的用途
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
Reichmann et al. Dopamine and Glutamate in Parkinson’s Disease: Biochemistry, Clinical Aspects, and Treatment
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa
McLean Reviews of medical journal articles
JP2024020094A (ja) 低用量グルタチオンの肌の明度向上剤としての使用
JP2007511577A (ja) （２ｓ，３ｓ）−２−（３−クロロフェニル）−３，５，５−トリメチル−２−モルホリノールの使用
Wolters Conventional Pharmacotherapy in ParkinsonTs Disease
TW200813038A (en) Combination preparations comprising SLV308 and L-DOPA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal